“US Plasma Therapeutics Market Research Report and Forecast 2023-2028” provides a deep and thorough evaluation of the plasma therapeutics market in the United States on the basis of fractionation products of plasma (Human Albumin, Plasma Derived Coagulation Factors, Immunoglobulins, Hyperimmune Globulins and A1PI) and disease type (Clotting Disorders, Immune Disorders, AATD and Others). Plasma therapeutics are essential, life-saving medications used by people with rare and complex conditions. They are manufactured using a fractionation procedure where the relevant plasma proteins are separated. They help replace missing or deficient proteins, and patients who depend on these treatments require regular infusions or injections throughout their lives. They are used to treat numerous rare diseases, including bleeding disorders and inhibitor deficiencies such as primary and secondary immunodeficiencies. Since they aid in better disease management, increase life expectancy and improve the quality of patient life, plasma therapeutics are gaining immense traction across the United States.
The US plasma therapeutics market is primarily driven by the rising prevalence of life-threatening diseases and neurological system disorders, such as idiopathic thrombocytopenic purpura (ITP), chronic inflammatory demyelinating polyneuropathy (CIPD), and multifocal motor neuropathy (MMN). Additionally, the rising geriatric population suffering from numerous diseases is more prone to infectious diseases due to weak immunity, which is positively influencing the market growth. Along with this, the increasing incidences of contagious diseases, such as hepatitis A&B, tetanus, and rabies, have augmented the product demand. Besides this, the escalating demand for platelet-rich plasma (PRP) in nerve injury, cardiac muscle injury, orthopedic, dermatology, and dental applications is propelling the market growth. Moreover, there has been increasing use of plasma fractionation products for treating coronavirus disease (COVID-19) across the country. In line with this, the surging adoption of plasma therapy to provide enhanced treatment for numerous body disorders, such as the knee, ankle, shoulder, and other parts, has catalyzed market growth. Furthermore, the rising investments in research and development (R&D) activities by biotechnology and pharmaceutical companies represent another major growth-inducing factor. Other factors, including favorable government policies, rising awareness levels among blood donors, easy availability of advanced protein fractionation procedures, increasing research partnerships, and inflating consumer disposable incomes, are also anticipated to drive the market further.
Beginning with a regional overview, the report explores the dynamics that have a strong influence on the US plasma therapeutics market and also impact its future growth. Taking 2022 as the base year, the report covers historical market scenario from 2017-2022 and provides forecasts till 2028. This includes the study of value and volume trends as well as pricing history. Growth inducing factors, market restraints and recent developments have also been analyzed in the report in order to provide deeper knowledge about the industry.
The report analyses the competitive structure of the US plasma therapeutics industry and provides the profiles of major players operating in the market. The price margins for the products, along with the various success and risk factors for manufacturers, have also been covered in the report. Moreover, in order to determine market attractiveness, the report analyses the US plasma therapeutics industry along the parameters of Porter’s Five Forces model. This model examines the degree of competition in the US plasma therapeutics industry by analysing the threat posed by new entrants and substitutes and the bargaining power of suppliers and buyers. SWOT analysis of the market has also been presented in the report, which highlights the strengths, weaknesses, opportunities and threats pertaining to the US plasma therapeutics industry. Furthermore, the value chain analysis of the US plasma therapeutics industry has also been covered in the report. This comprises all the activities in the value chain, such as the procurement of various raw materials, manufacturing, sales and distribution.
US Plasma Therapeutics Market Key Segments
Segmentation by Fractionation Products of Plasma
Segmentation by Disease Type
The price margins for the products along with various success and risk factors for manufacturers have also been covered in the report. Moreover, in order to determine market attractiveness, the report analyses the US plasma therapeutics industry along the parameters of the Porter’s Five Forces model. This model examines the degree of competition in the US plasma therapeutics market by analyzing the threats posed by new entrants and substitutes, and the bargaining power of suppliers and buyers. SWOT analysis of the market has also been presented in the report which highlights the strengths, weaknesses, opportunities and threats pertaining to the plasma therapeutics industry. Furthermore, the value chain analysis of the plasma therapeutics industry has also been covered in the report. This comprises of all the activities in the value chain, such as the procurement of various raw materials, manufacturing and sales of the products, and their distribution.
Key questions answered in the report include
The report is a result of exhaustive primary and secondary research undertaken by analysts having years of experience in the plasma therapeutics industry. All the qualitative and quantitative aspects of the industry have been covered and the collected data has been analyzed and presented in the form of easily comprehensible charts, graphs and tables.
Access Tailored Insights Designed for Your BusinessAccess Tailored Insights Designed for Your Business.
Personalize this research
Triangulate with your own data
Get data as per your format and definition
Gain a deeper dive on a specific application, geography, customer or competitor
Any level of personalization
© Copyright Syndicated Analytics 2024.